India’s P&G hygiene and healthcare posts Q3 sales fall on muted demand

BENGALURU, May 10 (Reuters) – India’s Procter & Gamble Hygiene & Healthcare Ltd. (PROC.NS) It reported a decline in quarterly sales on Wednesday, as demand for pandemic-specific health care products declined as new COVID cases continued to decline across the country.

The company said sales of its products, which range from Vicks inhalers to Whisper sanitary napkins, fell 1 percent to 8.81 billion rupees ($107.73 million) in the January-March quarter.

Led by Omicron’s sales increase over the same quarter a year ago, it was the company. he said. As the cases mount, Vicks VapoRub and the exchange file for use in demand for its health care products, including throat drops.

World Health Organization last week It ended Three years after the initial declaration of a Covid-19 international emergency.

It was unclear how much of the company’s revenue came from health care products.

India’s annual retail inflation rose in January, although it remained relatively high in the next two months, with higher inflation dampening consumer demand.

He said P&G Hygiene and Healthcare’s performance was “resilient” despite a “challenging operating environment.”

Profit rose to 1.65 billion rupees from 1.03 billion rupees a year ago. Due to certain tax adjustments, he benefited from a profit of 575 million rubles.

The company’s shares are down 6 percent this year.

Meanwhile, consumer goods and health supplement maker Dabur India Ltd (DABU.NS) i saw Quarterly margins were squeezed by discounts and higher material costs.

($1 = 81.7800 Indian Rupees)

Reporting by Dimple Gulwani in Bengaluru; Editing by Sohini Goswami

Our standards: The Thomson Reuters Trust Principles.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *